M D Carcao

List of Publications by Year
in descending order

172 papers	5,483 citations	87843 38 h-index	102432 66 g-index
174 all docs	174 docs citations	174 times ranked	3226 citing authors

#	Article	IF	Citations
1	Novel cysteine substitution p.(Cys1084Tyr) causes variable expressivity of qualitative and quantitative VWF defects. Blood Advances, 2022, , .	2.5	0
2	Safety and effectiveness of recombinant factor XIIIâ€A2 in congenital factor XIII deficiency: Realâ€world evidence. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12628.	1.0	3
3	How I approach: The workup and management of patients with progressive transformation of the germinal center. Pediatric Blood and Cancer, 2022, , e29638.	0.8	2
4	Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian realâ€world, multicenter, retrospective study. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12661.	1.0	4
5	First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results. Blood, 2022, 139, 3699-3707.	0.6	13
6	Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12) Tj ETQq0 0 0 rgBT /Overlock 10	1.0	7
7	Low dose prophylaxis and antifibrinolytics: Options to consider with proven benefits for persons with haemophilia. Haemophilia, 2022, 28, 26-34.	1.0	6
8	Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial. Blood, 2022, 140, 1156-1166.	0.6	2
9	Realâ€world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A followâ€up retrospective analysis. Haemophilia, 2021, 27, 19-25.	1.0	6
10	The use of rapamycin to treat vascular tumours and malformations: A single-centre experience. Paediatrics and Child Health, 2021, 26, e25-e32.	0.3	7
11	A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects. Thrombosis and Haemostasis, 2021, 121, 1326-1336.	1.8	12
12	Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors. Expert Review of Hematology, 2021, 14, 143-148.	1.0	16
13	Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study. Thrombosis and Haemostasis, 2021, 121, 1400-1408.	1.8	14
14	Fetal therapy using rapamycin for a rapidly enlarging, obstructive, cervical lymphatic malformation: a case report. Prenatal Diagnosis, 2021, 41, 884-887.	1.1	8
15	Updating the Canadian Hemophilia Outcomesâ€“Kidsâ€™ Life Assessment Tool (CHOâ€KLAT) in the era of extended halfâ€life clotting factor concentrates. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 403-411.	1.0	5
16	Measuring the impact of hemophilia on families: Development of the Hemophilia Family Impact Tool (Hâ€FIT). Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12519.	1.0	1
17	Patterns of joint damage in severe haemophilia A treated with prophylaxis. Haemophilia, 2021, 27, 666-673.	1.0	1
18	Factor product utilization and health outcomes in patients with haemophilia A and B on extended halfâ€life concentrates: A Canadian observational study of realâ€world outcomes. Haemophilia, 2021, 27, 751-759.	1.0	9

#	Article	IF	Citations
19	Immune tolerance induction using Fcâ€fusionâ€protein recombinant factor IX in severe haemophilia B. Haemophilia, 2021, 27, e776-e779.	1.0	0
20	The impact of extended halfâ€life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12601.	1.0	5
21	Magnetic resonance imaging in boys with severe hemophilia A: Serial and endâ€ofâ€study findings from the Canadian Hemophilia Primary Prophylaxis Study. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12565.	1.0	4
22	Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP). Patient Preference and Adherence, 2021, Volume 15, 2443-2454.	0.8	1
23	Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age. Blood, 2021, 138, 3195-3195.	0.6	1
24	Excess weight gain in the paediatric bleeding disorders population: Impact of the COVIDâ€19 Pandemic. Haemophilia, 2021, , .	1.0	2
25	Efficacy of rFVIIIFc for First-Time Immune Tolerance Induction (ITI) Therapy: Final Results from the Global, Prospective VerITI-8 Study. Blood, 2021, 138, LBA-5-LBA-5.	0.6	1
26	Measuring the impact of changing from standard halfâ€life (SHL) to extended halfâ€life (EHL) FVIII prophylaxis on healthâ€related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHOâ€KLAT tool. Haemophilia, 2020, 26, 73-78.	1.0	15
27	WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia, 2020, 26, 1-158.	1.0	915
28	Long-Term Safety and Efficacy of Nonacog Beta Pegol (N9-GP) Administered for at Least 5 Years in Previously Treated Children with Hemophilia B. Thrombosis and Haemostasis, 2020, 120, 737-746.	1.8	8
29	Longâ€term followâ€up of neonatal intracranial haemorrhage in children with severe haemophilia. British Journal of Haematology, 2020, 190, e101-e104.	1.2	3
30	IVMP+IVIG raises platelet counts faster than IVIG alone: results of a randomized, blinded trial in childhood ITP. Blood Advances, 2020, 4, 1492-1500.	2.5	16
31	Genotypeâ€“phenotype correlation in children with hereditary spherocytosis. British Journal of Haematology, 2020, 191, 486-496.	1.2	46
32	Fixed doses of N8â€GP prophylaxis maintain moderateâ€toâ€mild factor VIII levels in the majority of patients with severe hemophilia A. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 542-554.	1.0	17
33	Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood, 2019, 134, 317-320.	0.6	71
34	Abnormal fibrinolysis recognized by thromboelastography in a case of severe bleeding with normal coagulation and platelet function, leads to detection of a novel SERPINF2 variant causing severe alphaâ€2â€antiplasmin deficiency. British Journal of Haematology, 2019, 186, e198-e201.	1.2	1
35	Dieulafoy lesions and PHACE syndrome. Pediatric Dermatology, 2019, 36, 902-905.	0.5	3
36	Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients. Blood, 2019, 134, 880-891.	0.6	35

#	Article	IF	Citations
37	Comparative pharmacokinetics of two extended halfâ€life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?. Journal of Thrombosis and Haemostasis, 2019, 17, 1085-1096.	1.9	34
38	The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia, 2019, 25, 676-684.	1.0	75
39	Mild Hereditary Spherocytosis without Accompanying Hereditary Haemochromatosis: An Unrecognised Cause of Iron Overload. Acta Haematologica, 2019, 141, 256-260.	0.7	2
40	Hemophilia in a Changing Treatment Landscape. Hematology/Oncology Clinics of North America, 2019, 33, 409-423.	0.9	21
41	Inhibitors: A Need for Eradication?. Acta Haematologica, 2019, 141, 151-155.	0.7	15
42	An Update on rFVIIa Use in Females with Rare Bleeding Disorders. Blood, 2019, 134, 1119-1119.	0.6	2
43	Clingen Coagulation Factor Deficiency Variant Curation Expert Panel: Meeting the Need for Recommendations to Curate Variants in the Coagulation Factor Genes. Blood, 2019, 134, 5794-5794.	0.6	1
44	Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. Thrombosis and Haemostasis, 2018, 118, 451-460.	1.8	22
45	Results after laparoscopic partial splenectomy for children with hereditary spherocytosis: Are outcomes influenced by genetic mutation?. Journal of Pediatric Surgery, 2018, 53, 973-975.	0.8	9
46	Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A withÂinhibitorsâ€"A retrospective analysis. Haemophilia, 2018, 24, 245-252.	1.0	39
47	A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies. Expert Review of Hematology, 2018, 11, 87-97.	1.0	14
48	Desmopressin in moderate hemophilia A patients: a treatment worth considering. Haematologica, 2018, 103, 550-557.	1.7	23
49	Glanzmann thrombasthenia platelets compete with transfused platelets, reducing the haemostatic impact of platelet transfusions. British Journal of Haematology, 2018, 181, 410-413.	1.2	13
50	Immunogenicity, efficacy and safety of Nuwiq^{Â®} (humanâ€cl rh<scp>FVIII</scp>) in previously untreated patients with severe haemophilia Aâ€"Interim results from the NuProtect Study. Haemophilia, 2018, 24, 211-220.	1.0	26
51	Vaccinations are not associated with inhibitor development in boys with severe haemophilia A. Haemophilia, 2018, 24, 283-290.	1.0	24
52	Onceâ€weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9â€GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigmâ„¢ trials. Haemophilia, 2018, 24, 911-920.	1.0	11
53	A Quality Improvement Bundle to Improve Informed Choice for Children With Typical, Newly Diagnosed Immune Thrombocytopenia. Journal of Pediatric Hematology/Oncology, 2018, 40, e537-e543.	0.3	3
54	Prophylaxis reâ€visited: The potential impact of novel factor and nonâ€factor therapies on prophylaxis. Haemophilia, 2018, 24, 845-848.	1.0	5

#	Article	IF	Citations
55	Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort. Lancet Haematology,the, 2018, 5, e252-e260.	2.2	31
56	Idiopathic pulmonary arterial hypertension â€“ a unrecognized cause of highâ€shear highâ€flow haemostatic defects (otherwise referred to as acquired von Willebrand syndrome) in children. British Journal of Haematology, 2018, 183, 267-275.	1.2	12
57	The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 2106-2110.	1.9	11
58	NBEAL2 mutations and bleeding in patients with gray platelet syndrome. Platelets, 2018, 29, 632-635.	1.1	29
59	99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry. Blood, 2018, 132, 2472-2472.	0.6	0
60	Real-World Data of Immune Tolerance Induction Using rFVIIIFc in Subjects With Severe Hemophilia A With Inhibitors at High Risk for ITI Failure. Blood, 2018, 132, 2500-2500.	0.6	1
61	Effect of moderate intensity exercise on haemostatic capacity in adults with haemophilia A and B: pilot study. Haemophilia, 2017, 23, e162-e165.	1.0	5
62	Pharmacokinetics of a novel extended halfâ€life glyco<scp>PEG</scp>ylated factor <scp>IX</scp>, nonacog beta pegol (N9â€<scp>GP</scp>) in previously treated patients with haemophilia B: results from two phase 3 clinical trials. Haemophilia, 2017, 23, 547-555.	1.0	22
63	Utility of factor VIII and factor VIII to von Willebrand factor ratio in identifying 277 unselected carriers of hemophilia A. American Journal of Hematology, 2017, 92, E94-E96.	2.0	10
64	An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia. Haemophilia, 2017, 23, e444-e447.	1.0	3
65	Comparing the burden of illness of haemophilia between resourceâ€constrained and unconstrained countries: the SÃ£o Pauloâ€“Toronto Hemophilia Study. Haemophilia, 2017, 23, 682-688.	1.0	19
66	An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia. Haemophilia, 2017, 23, e447-e450.	1.0	4
67	Insight into healthâ€related quality of life of young children with haemophilia B treated with longâ€acting nonacog beta pegol recombinant factor IX. Haemophilia, 2017, 23, e222-e224.	1.0	9
68	Switching to extended halfâ€life products in Canada â€“ preliminary data. Haemophilia, 2017, 23, e365-e367.	1.0	30
69	Intracranial haemorrhage in children and adolescents with severe haemophilia A or B â€“ the impact of prophylactic treatment. British Journal of Haematology, 2017, 179, 298-307.	1.2	56
70	Developing the First Recombinant Factor XIII for Congenital Factor XIII Deficiency: Clinical Challenges and Successes. Seminars in Thrombosis and Hemostasis, 2017, 43, 059-068.	1.5	15
71	Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective. Haemophilia, 2017, 23, 11-24.	1.0	63
72	Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors. Thrombosis and Haemostasis, 2017, 117, 2274-2282.	1.8	13

#	Article	IF	Citations
73	Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors. Thrombosis and Haemostasis, 2016, 115, 729-737.	1.8	18
74	Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels. Thrombosis and Haemostasis, 2016, 115, 913-920.	1.8	27
75	The role of previously untreated patient studies in understanding the development of <scp>FVIII</scp> inhibitors. Haemophilia, 2016, 22, 22-31.	1.0	20
76	Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy. Seminars in Thrombosis and Hemostasis, 2016, 42, 018-029.	1.5	19
77	Pilot study of onceâ€¤â€day prophylaxis for youth and young adults with severe haemophilia A. Haemophilia, 2016, 22, e401-5.	1.0	5
78	An institutional pilot study to investigate physical activity patterns in boys with haemophilia. Haemophilia, 2016, 22, e383-9.	1.0	15
79	Impact of aerobic exercise on haemostatic indices in paediatric patients with haemophilia. Thrombosis and Haemostasis, 2016, 115, 1120-1128.	1.8	13
80	Nonacog beta pegol in previously treated children with hemophilia B: results from an international openâ€label phase 3 trial. Journal of Thrombosis and Haemostasis, 2016, 14, 1521-1529.	1.9	42
81	Factor VIII/factor IX prophylaxis for severe hemophilia. Seminars in Hematology, 2016, 53, 3-9.	1.8	19
82	Safety and Efficacy of Recombinant Factor XIII (FXIII) in Patients with Congenital FXIII A-Subunit Deficiency, Results from the Mentorâ„¢2 Trial. Blood, 2016, 128, 2573-2573.	0.6	0
83	Optimising musculoskeletal care for patients with haemophilia. European Journal of Haematology, 2015, 95, 11-21.	1.1	10
84	Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network. Journal of Thrombosis and Haemostasis, 2015, 13, 1585-1589.	1.9	44
85	Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades. Haematologica, 2015, 100, e84-e86.	1.7	27
86	Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy. Blood Coagulation and Fibrinolysis, 2015, 26, 383-388.	0.5	46
87	Pharmacokinetic characterization of recombinant factor XIII (FXIII)â€A2 across age groups in patients with FXIII Aâ€subunit congenital deficiency. Haemophilia, 2015, 21, 380-385.	1.0	13
88	Vincristine for Successful Treatment of Steroid-Dependent Infantile Hemangiomas. Pediatrics, 2015, 135, e1501-e1505.	1.0	22
89	Switching from current factor VIII (FVIII) to longer acting <scp>FVIII</scp> concentrates â€“ what is the real potential benefit?. Haemophilia, 2015, 21, 297-299.	1.0	7
90	Acquired von Willebrand syndrome in paediatric patients with congenital heart disease: challenges in the diagnosis and management of this rare condition. Haemophilia, 2015, 21, e89-92.	1.0	18

#	Article	IF	Citations
91	Individualizing Factor Replacement Therapy in Severe Hemophilia. Seminars in Thrombosis and Hemostasis, 2015, 41, 864-871.	1.5	20
92	Hemophilia Prophylaxis No Longer Just for Children without Inhibitors - Increasing Use of Prophylaxis in Other Groups (children with inhibitors and adults with and without inhibitors). Blood, 2015, 126, 3535-3535.	0.6	2
93	Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia, 2014, 20, 99-105.	1.0	61
94	Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010. Haemophilia, 2014, 20, 771-776.	1.0	29
95	Desmopressin (<scp>DDAVP</scp>) in the management of patients with congenital bleeding disorders. Haemophilia, 2014, 20, 158-167.	1.0	66
96	Safety, Efficacy and Pharmacokinetics of Nonacog Beta Pegol (N9-GP) in Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Pediatric Hemophilia B Patients. Blood, 2014, 124, 1513-1513.	0.6	4
97	Clearance and Genetic Variability of Von Willebrand Factor Are Major Determinants of the Pharmacokinetic Behavior of Factor VIII Concentrates in the Treatment of Pediatric Hemophilia A. Blood, 2014, 124, 473-473.	0.6	0
98	Impact of Exercise on Hemostasis in Boys with Hemophilia a (HA) and B (HB): Principal Findings of the Sickkids Hemophilia Exercise Study. Blood, 2014, 124, 1493-1493.	0.6	0
99	Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia, 2013, 19, 76-81.	1.0	99
100	Symposium on congenital and acquired bleeding disorders in children (in honor of the lifetime) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 387 2013, 60, S1.	0.8	0
101	Inherited Abnormalities of Coagulation. Pediatric Clinics of North America, 2013, 60, 1419-1441.	0.9	34
102	Intracranial haemorrhage in von <scp>W</scp>illebrand disease: a report on six cases. Haemophilia, 2013, 19, 602-606.	1.0	17
103	Consequences of delayed therapy for sportsâ€related bleeds in patients with mildâ€toâ€moderate haemophilia and type 3 von Willebrand's disease not on prophylaxis. Haemophilia, 2013, 19, e264-7.	1.0	11
104	Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood, 2013, 121, 4046-4055.	0.6	287
105	Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A. Blood, 2013, 121, 3946-3952.	0.6	59
106	Pharmacokinetic Characterisation Of Recombinant FXIII Across Age Groups In Patients With FXIII Subunit A Congenital Deficiency. Blood, 2013, 122, 3613-3613.	0.6	0
107	The Diagnosis and Management of Congenital Hemophilia. Seminars in Thrombosis and Hemostasis, 2012, 38, 727-734.	1.5	75
108	Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. Blood, 2012, 119, 5111-5117.	0.6	116

#	Article	IF	Citations
109	Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabachâ€“Merritt phenomenon. Pediatric Blood and Cancer, 2012, 59, 934-938.	0.8	107
110	DDAVP responsiveness in children with mild or moderate haemophilia A correlates with age, endogenous FVIII:C level and with haemophilic genotype. Haemophilia, 2012, 18, 50-55.	1.0	38
111	Low prevalence of inhibitor antibodies in the Canadian haemophilia population. Haemophilia, 2012, 18, e254-9.	1.0	11
112	Haemophilia prophylaxis: how can we justify the costs?. Haemophilia, 2012, 18, 680-684.	1.0	17
113	Expanded phenotype-genotype correlations in a pediatric population with typeÂ1 von Willebrand disease. Journal of Thrombosis and Haemostasis, 2011, 9, 1752-1760.	1.9	13
114	Therapeutic consequences for misdiagnosis of Type 2N von Willebrand disease. Pediatric Blood and Cancer, 2011, 57, 1081-1083.	0.8	16
115	Genetic analysis of inherited bone marrow failure syndromes from one prospective, comprehensive and population-based cohort and identification of novel mutations. Journal of Medical Genetics, 2011, 48, 618-628.	1.5	55
116	Devising a best practice approach to prophylaxis in boys with severe haemophilia: evaluation of current treatment strategies. Haemophilia, 2010, 16, 4-9.	1.0	15
117	Prophylaxis in haemophilia with inhibitors: update from international experience. Haemophilia, 2010, 16, 16-23.	1.0	42
118	Dental disease in type 3 Von Willebrand disease: a neglected problem. Haemophilia, 2010, 16, 943-948.	1.0	5
119	Recombinant Factor XIII, Safe and Novel Treatment for Congenital Factor XIII Deficiency. Blood, 2010, 116, 20-20.	0.6	3
120	Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care. Haemophilia, 2009, 15, 227-239.	1.0	64
121	Acute haemarthrosis of the hip joint: rapid convalescence following ultrasoundâ€guided needle aspiration. Haemophilia, 2009, 15, 390-393.	1.0	12
122	Sideâ€effects and venous access issues with immune tolerance therapy. Haemophilia, 2009, 15, 494-500.	1.0	6
123	The application of bypassingâ€agent prophylaxis in haemophilia A patients with inhibitors: a meeting report. Haemophilia, 2009, 15, 959-965.	1.0	11
124	A comprehensive review of rFVIIa use in a tertiary care pediatric center. Pediatric Blood and Cancer, 2008, 50, 1013-1017.	0.8	17
125	Valproate-induced pure red cell aplasia and megakaryocyte dysplasia. British Journal of Haematology, 2008, 141, 133-133.	1.2	8
126	A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia, 2008, 14, 281-286.	1.0	45

#	Article	IF	Citations
127	The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia, 2008, 14, 923-930.	1.0	96
128	On-Label Versus Off-Label Use of Recombinant Activated Factor VII: A Comprehensive Review of Use in Two Canadian Centers. Seminars in Hematology, 2008, 45, S68-S71.	1.8	3
129	Kaposiform Hemangioendothelioma Presenting Antenatally With a Pericardial Effusion. Journal of Pediatric Hematology/Oncology, 2008, 30, 761-763.	0.3	18
130	Definitions for haemophilia prophylaxis and its outcomes: The Canadian Consensus Study. Haemophilia, 2007, 13, 12-20.	1.0	46
131	Sonography for assessment of haemophilic arthropathy in children: a systematic protocol. Haemophilia, 2007, 13, 293-304.	1.0	95
132	Prophylaxis in the haemophilia population-optimizing therapy. Haemophilia, 2007, 13, 227-232.	1.0	6
133	Intracranial bleeding in haemophilia beyond the neonatal period â€“ the role of CT imaging in suspected intracranial bleeding. Haemophilia, 2007, 13, 552-559.	1.0	43
134	Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group. Haemophilia, 2007, 14, 071115150757005-???.	1.0	24
135	Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. Haemophilia, 2006, 12, 7-18.	1.0	101
136	Pharmacokinetics of recombinant factor VIII (Kogenate-FSï¿½) in children and causes of inter-patient pharmacokinetic variability. Haemophilia, 2006, 12, 40-49.	1.0	37
137	DDAVP-Induced Hyponatremia in Young Children. Journal of Pediatric Hematology/Oncology, 2005, 27, 330-332.	0.3	37
138	Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment. Transfusion Medicine, 2005, 15, 145-150.	0.5	34
139	Clostridium septicum Myonecrosis in Congenital Neutropenia. Pediatrics, 2004, 114, e757-e760.	1.0	24
140	Cost-utility analysis in evaluating prophylaxis in haemophilia. Haemophilia, 2004, 10, 50-57.	1.0	8
141	A prospective, longitudinal study of central venous catheter-related deep venous thrombosis in boys with hemophilia. Journal of Thrombosis and Haemostasis, 2004, 2, 737-742.	1.9	60
142	More on: intensive factor VIII exposure and inhibitor development in mild hemophilia A. Journal of Thrombosis and Haemostasis, 2004, 2, 677-677.	1.9	7
143	Prophylactic factor replacement in hemophilia. Blood Reviews, 2004, 18, 101-113.	2.8	45
144	Childhood Acute Myelomonocytic Leukemia (AML-M4) Presenting as Catastrophic Antiphospholipid Antibody Syndrome. Journal of Pediatric Hematology/Oncology, 2004, 26, 327-330.	0.3	32

#	Article	IF	Citations
145	Novel and Clinically Significant Factors Influencing the Pharmacokinetic Variability of Recombinant Factor VIII (Kogenate-FS) in Children.. Blood, 2004, 104, 3991-3991.	0.6	1
146	The Care of Immigrant Children with Haemophilia.. Blood, 2004, 104, 4013-4013.	0.6	0
147	Central venous catheter-related thrombosis presenting as superior vena cava syndrome in a haemophilic patient with inhibitors. Haemophilia, 2003, 9, 578-583.	1.0	36
148	Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. Journal of Thrombosis and Haemostasis, 2003, 1, 1228-1236.	1.9	168
149	FcÎ³ receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura. British Journal of Haematology, 2003, 120, 135-141.	1.2	71
150	Childhood Acute Immune Thrombocytopenic Purpura: 20 Years Later. Seminars in Thrombosis and Hemostasis, 2003, 29, 605-618.	1.5	42
151	Desmopressin (DDAVP) Responsiveness in Children With von Willebrand Disease. Journal of Pediatric Hematology/Oncology, 2003, 25, 874-879.	0.3	51
152	Sustained Cyclosporine-Induced Erythropoietic Response in Identical Male Twins With Diamond-Blackfan Anemia. Journal of Pediatric Hematology/Oncology, 2003, 25, 914-918.	0.3	10
153	Adverse Outcomes in Primary Hemophagocytic Lymphohistiocytosis. Journal of Pediatric Hematology/Oncology, 2002, 24, 550-554.	0.3	43
154	DDAVP challenge tests in boys with mild/moderate haemophilia A*. British Journal of Haematology, 2002, 117, 947-951.	1.2	33
155	Assessment of thrombocytopenic disorders using the Platelet Function Analyzer (PFA-100Â®)*. British Journal of Haematology, 2002, 117, 961-964.	1.2	37
156	IDENTIFICATION OF TWO NEW Î±-THALASSEMIA MUTATIONS IN EXON 2 OF THE Î±1-GLOBIN GENE. Hemoglobin, 2001, 25, 391-396.	0.4	9
157	Hemoglobin H (Hb H) disease in Canada: Molecular diagnosis and review of 116 cases. American Journal of Hematology, 2001, 68, 11-15.	2.0	27
158	von Willebrand Disease in a Pediatric-based Population - Comparison of Type 1 Diagnostic Criteria and Use of the PFA-100Â® and a von Willebrand Factor/Collagen-binding Assay. Thrombosis and Haemostasis, 2000, 84, 401-409.	1.8	123
159	Approach to the investigation and management of immune thrombocytopenic purpura in children. Seminars in Hematology, 2000, 37, 299-314.	1.8	32
160	von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay. Thrombosis and Haemostasis, 2000, 84, 401-9.	1.8	20
161	Compound Heterozygosity for Hb S and Hb G-Copenhagen. Hemoglobin, 1999, 23, 379-381.	0.4	2
162	MRI findings in macrocephaly-cutis marmorata telangiectatica congenita. American Journal of Medical Genetics Part A, 1998, 76, 165-167.	2.4	36

#	Article	IF	Citations
163	Renal-cell carcinoma in children: A different disorder from its adult counterpart?. Medical and Pediatric Oncology, 1998, 31, 153-158.	1.0	84
164	The Platelet Function Analyzer (PFA-100Â®): a novel in-vitro system for evaluation of primary haemostasis in children. British Journal of Haematology, 1998, 101, 70-73.	1.2	142
165	Intravenous Immunoglobulin G and Anti-D as Therapeutic Interventions in Immune Thrombocytopenic Purpura. Transfusion Science, 1998, 19, 279-288.	0.6	20
166	Use of the PFA-100^{Â®}in the Assessment of Primary, Platelet-Related Hemostasis in a Pediatric Setting. Seminars in Thrombosis and Hemostasis, 1998, 24, 523-529.	1.5	41
167	Shortâ€course oral prednisone therapy in children presenting with acute immune thrombocytopenic purpura (ITP). Acta Paediatrica, International Journal of Paediatrics, 1998, 87, 71-74.	0.7	34
168	MRI findings in macrocephalyâ€cutis marmorata telangiectatica congenita. American Journal of Medical Genetics Part A, 1998, 76, 165-167.	2.4	2
169	Renalâ€cell carcinoma in children: A different disorder from its adult counterpart?. Medical and Pediatric Oncology, 1998, 31, 153-158.	1.0	3
170	Sequential use of intravenous and oral acyclovir in the therapy of varicella in immunocompromised children. Pediatric Infectious Disease Journal, 1998, 17, 626-631.	1.1	35
171	MRI findings in macrocephaly-cutis marmorata telangiectatica congenita. American Journal of Medical Genetics Part A, 1998, 76, 165-7.	2.4	2
172	The Newborn. , 0, , 205-223.		0